N/A N=30 Randomized Treatment

Transcutaneous Electrical Nerve Stimulation After Total Hip Arthroplasty

Transcutaneous Electric Nerve Stimulation · Pain

Bottom Line

View on ClinicalTrials.gov: NCT03046212 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2017

Primary outcome: Primary: Change in Pain Level From Baseline to 45 Minutes — 1.2; 3.7 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Transcutaneous electrical nerve stimulation (Device); Exercises (Other)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: Hospital de Clinicas de Porto Alegre
Primary completion: Aug 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Pain Level From Baseline to 45 Minutes	1.2; 3.7	—
SECONDARY Change in Hip Range of Motion From Baseline to 45 Minutes	22.5; 20.5	—
SECONDARY Number of Participants Who Received Morphine Within 24 Hours	6; 3	—

Summary

Transcutaneous electrical nerve stimulation (TENS) is characterized by the application of an electric pulsed current through electrodes positioned on the skin. It can be an alternative for pain management after surgery for total hip arthroplasty (THA), since it is a safe and cost-effective therapeutic tool, allowing the patient to move early due to pain relief. Therefore, the study aims to evaluate the acute effects of TENS associated with standard physical therapy compared with standard physical therapy on the intensity of pain, hip range of motion and morphine consumption in the rehabilitation of patients after THA.

Eligibility Criteria

Inclusion Criteria

patients who underwent THA surgery due to primary or secondary coxarthrosis; both sexes; age between 40 and 90 years.

Exclusion Criteria

patients who refused to participate of the study; THA indication for fractures and bone tumors; THA review surgery; postoperative infection; congenital anatomical alterations; neurological disorders; lack of understanding of commands; sensitivity alterations in the lower limbs; decompensated heart disease or cardiac pacemaker use.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03046212). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.